» Articles » PMID: 9298922

The Influence of a Novel Pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine Methylester and L-arginine Effects on Stomach Mucosa Integrity and Blood Pressure

Abstract

The known effects of a novel stomach pentadecapeptide BPC157 (10 microg or 10 ng/kg), namely its salutary activity against ethanol (96%, i.g.)-induced gastric lesions (simultaneously applied i.p.) and in blood pressure maintenance (given i.v.), were investigated in rats challenged with a combination of N(G)-nitro-L-arginine methylester (L-NAME) (5 mg/kg i.v.), a competitive inhibitor of endothelium nitric oxide (NO)-generation and NO precursor, L-arginine (200 mg/kg i.v.) (D-arginine was ineffective). In the gastric lesions assay, NO agents were given 5 min before ethanol injury and BPC 157 medication. Given alone, BPC157 had an antiulcer effect, as did L-arginine, but L-NAME had no effect. L-NAME completely abolished the effect of L-arginine, whereas it only attenuated the effect of BPC 157. After application of the combination of L-NAME + L-arginine, the BPC157 effect was additionally impaired. In blood pressure studies, compared with L-arginine, pentadecapeptide BPC 157 (without effect on basal normal values) had both a mimicking effect (impaired L-NAME-blood pressure increase, when applied prophylactically and decreased already raised L-NAME values, given at the time of the maximal L-NAME-blood pressure increase (i.e., 10 min after L-NAME)) and preventive activity (L-arginine-induced moderate blood pressure decrease was prevented by BPC 157 pretreatment). When BPC 157 was given 10 min after L-NAME + L-arginine combination, which still led to a blood pressure increase, its previously clear effect (noted in L-NAME treated rats) disappeared. In vitro, in gastric mucosa from rat stomach tissue homogenates, BPC 157, given in the same dose (100 microM) as L-arginine, induced a comparable generation of NO. But, BPC 157 effect could not be inhibited by L-NAME, even when L-NAME was given in a tenfold (100 versus 1000 microM) higher dose than that needed for inhibition of the L-arginine effect. NO synthesis was blunted when the pentadecapeptide BPC 157 and L-arginine were combined. In summary, BPC 157 could interfere with the effects of NO on both gastric mucosal integrity and blood pressure maintenance in a specific way, especially with L-arginine, having a more prominent and/or particularly different effect from that of NO.

Citing Articles

Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.

Jozwiak M, Bauer M, Kamysz W, Kleczkowska P Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005999 PMC: 11859134. DOI: 10.3390/ph18020185.


Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats.

Matek D, Matek I, Staresinic E, Japjec M, Bojanic I, Boban Blagaic A Pharmaceutics. 2025; 17(1).

PMID: 39861766 PMC: 11768438. DOI: 10.3390/pharmaceutics17010119.


New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection.

Sikiric P, Sever M, Krezic I, Vranes H, Kalogjera L, Smoday I Inflammopharmacology. 2024; 32(5):3119-3161.

PMID: 38980576 DOI: 10.1007/s10787-024-01499-8.


The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity.

Sikiric P, Boban Blagaic A, Strbe S, Beketic Oreskovic L, Oreskovic I, Sikiric S Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675421 PMC: 11053547. DOI: 10.3390/ph17040461.


Stable Gastric Pentadecapeptide BPC 157 Therapy: Effect on Reperfusion Following Maintained Intra-Abdominal Hypertension (Grade III and IV) in Rats.

Tepes M, Krezic I, Vranes H, Smoday I, Kalogjera L, Zizek H Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004420 PMC: 10675657. DOI: 10.3390/ph16111554.